Sensorion are the study sponsor and the objective of this study is to investigate the safety
and pharmacokinetic (PK) profile of SENS 401 in humans after a single and repeat dose
administration and to confirm that, there is no interconversion of the (R) enantiomer to the
(S) enantiomer.
The study only involves the one drug, referred to as SENS-401.The key objective is to assess
the safety of SENS 401 after multiple doses in healthy subjects.
The population who are eligible to take part in the study are healthy male and female,
non-smoking volunteers, aged between 18 and 50 years, as determined by screening tests at
Simbec.
Participation in the trial will last for about 3 weeks (from first screening to final end of
study visit).